New antibody drug aims to ease endometriosis pain in major trial

NCT ID NCT07318688

Recruiting now Symptom relief Sponsor: Hope Medicine (Nanjing) Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This Phase 3 trial tests HMI-115, a monoclonal antibody, in 540 women with moderate to severe endometriosis pain. Participants receive either the drug or a placebo for 24 weeks, with a 28-week extension. The goal is to see if HMI-115 reduces menstrual and pelvic pain better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HMI-115 (a human monoclonal antibody)
What this could lead to: If it works, this could offer a new non-hormonal option to reduce endometriosis pain for women.
What could go wrong: This is still an early Phase 3 trial, so results may not confirm benefit. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIOSIS

Contacts and locations

Locations

Nanjing Women and children's healthcare hospital
NOT_YET_RECRUITING

Nanning, Jiangsu, China
Peking Union Medical College Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100703, China
Second Affiliated Hospital of Soochow University
RECRUITING

Suzhu, Jiangsu, China
The International Peace Maternity and Child Health Hospital of the China Welfare Institute
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, China
Tianjin Medical University General Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.